Equillium

Equillium PP&E per Employee

The PP&E per Employee of Equillium (EQ) as of Nov 2, 2026 is 121,692.31 USD. In the previous year, PP&E per Employee was 18,230.77 USD — a change of 567.51% (higher).

PP&E per Employee

121,692.31USD

YoY

567.51%

Last updated:

PP&E per Employee of Equillium is 2022 121,692.31 USD. PP&E per Employee of Equillium was 2021 18,230.77 USD. It decreases by 567.51% higher compared to the previous year.

The Equillium PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2017
159.77 USD
Jan 1, 2018
4,923.08 USD
Jan 1, 2019
7,153.85 USD
Jan 1, 2020
18,384.62 USD
Jan 1, 2021
18,230.77 USD
Jan 1, 2022
121,692.31 USD
The Equillium PP&E per Employee history
YEARPP&E per EmployeeYoY
121,692.31USD+567.51%
18,230.77USD-0.84%
18,384.62USD+156.99%
7,153.85USD+45.31%
4,923.08USD+2,981.37%
159.77USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Equillium Stock analysis

What does Equillium do? Equillium Inc is an emerging biotechnology company specializing in the research and development of therapies for the treatment of inflammatory and autoimmune diseases. The company was founded in 2017 by a group of experienced biotech entrepreneurs who aim to develop innovative and effective treatment methods to improve patients' quality of life. Equillium's business model focuses on the discovery and development of new therapies based on the modulation of the CD6 signaling pathway, a central regulator of the immune system. Equillium's technology aims to modulate the immune system to suppress an inflammatory response associated with autoimmune and other inflammatory diseases. The company collaborates closely with leading university research laboratories and experts in the field to develop effective therapies. Equillium targets a wide range of disease areas, including autoimmune diseases such as lupus, psoriasis, and Crohn's disease. The company has also developed a program to treat COVID-19, aiming to reduce the immune-mediated inflammatory response associated with severe cases of COVID-19. Equillium's product portfolio includes EQ001, a monoclonal antibody used for the treatment of lupus and other autoimmune diseases. EQ001 blocks the CD6 signaling pathway, thereby reducing inflammatory responses that attack healthy tissues in the body. The company is also working on developing a novel platform technology to explore additional therapy options based on the CD6 signaling pathway. Equillium has a strong funding base and is supported by some of the most renowned biotech investors. The company has a comprehensive pipeline of potential therapies that are intended to address a variety of indications in the future. Overall, Equillium's advanced biotechnological research and development have contributed to the discovery of new and effective ways to treat inflammatory and autoimmune diseases. The company is well-positioned to expand in this area of medicine and improve therapy options for patients worldwide. Equillium is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Equillium stock

PP&E per Employee of Equillium is 121,692.31 USD in 2022.

PP&E per Employee of Equillium changed from 18,230.77 USD to 121,692.31 USD, representing a 567.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Equillium since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Equillium historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Equillium

All Key Metrics — Equillium